Tellus Therapeutics Awarded NINDS SBIR Funding for Development of TT-20 for Treatment of Neonatal Brain Injury
$696,000 Phase I award will support drug product formulation and in vivo pharmacokinetic study to enable an IND application for First-in-Neonate clinical trial DURHAM, NC, UNITED STATES, December 7, 2020 /EINPresswire.com/ -- Tellus Therapeutics, a …